Market Cap 12.02B
Revenue (ttm) 0.00
Net Income (ttm) -1.08B
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 2,724,900
Avg Vol 5,626,062
Day's Range N/A - N/A
Shares Out 776.16M
Stochastic %K 59%
Beta -1.26
Analysts Sell
Price Target $27.98

Company Profile

Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies. Its lead development candidate is ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis for the treatment of non-small lung cancer (NSCLC) and colorectal cancer (CRC). The company has also combined ivonescimab with chemotherapy, which is in phase III clinical...

Industry: Biotechnology
Sector: Healthcare
Phone: 305 203 2034
Address:
601 Brickell Key Drive, Suite 1000, Miami, United States
Dragonland
Dragonland Jul. 10 at 4:05 PM
$SMMT Holding up well considering rest of biotech is a deep red bloodbath today. When they take a sector down, they really don't spare anyone.
0 · Reply
Stbruce1978
Stbruce1978 Jul. 10 at 3:48 PM
$SMMT Very unscientific data point – from Aug 2025 thru May 2026, 100% of my $SMMT allocation was on the fully paid lending list (meaning the shares were actively short by someone else). Starting in June that number dropped to 18% of my allocation. Short interest is drying up – still elevated but not the extremes we saw prior. That’s a positive from a sentiment standpoint. It also means people who are excited for a short squeeze, should probably temper their expectations on that occurring.
1 · Reply
TruthBroker2
TruthBroker2 Jul. 9 at 6:26 PM
$SMMT Fridays Payday.
0 · Reply
SmokeWagon
SmokeWagon Jul. 9 at 3:59 PM
$SMMT !!!
0 · Reply
Megabyte48
Megabyte48 Jul. 9 at 10:40 AM
$SMMT Get over that 16$ today
0 · Reply
TruthBroker2
TruthBroker2 Jul. 8 at 11:20 PM
0 · Reply
HP18
HP18 Jul. 8 at 6:32 PM
$SLS Cleared all my positions in $CAPR and $SMMT to purchase more $SLS shares as can't miss this cheap buying opportunity. Still time to get back in $CAPR before the fda outcome deadline in August.
3 · Reply
SmokeWagon
SmokeWagon Jul. 8 at 2:34 PM
$SMMT !!!
0 · Reply
BapoRothstein
BapoRothstein Jul. 8 at 1:52 AM
$SMMT Chilling with Big Rob at Bob’s Big Boy. We’re waiting on Dr. Clow to meet us. After she gets here we’re going to eat salads with delicious blue cheese dressing and laugh, country club style, at all smelly poor people doubters. And then we’re riding together to massive gains on this excellent stock. Don’t hate me, bro. I don’t make the rules.
0 · Reply
Merlintrader
Merlintrader Jul. 7 at 9:12 PM
$SMMT Summit Therapeutics (Nasdaq: $SMMT): Ivonescimab, PD-1/VEGF Bispecifics and the High-Stakes Oncology Platform Bet https://www.merlintrader.com/summit-therapeutics-stock-hub/
0 · Reply
Latest News on SMMT
Summit Therapeutics falls -10.2%

2026-06-10T16:07:19.000Z - 4 weeks ago

Summit Therapeutics falls -10.2%


Summit Therapeutics Transcript: AGM 2026

Jun 10, 2026, 8:30 AM EDT - 4 weeks ago

Summit Therapeutics Transcript: AGM 2026


Summit Therapeutics announces $500M common stock offering

2026-06-09T20:50:10.000Z - 4 weeks ago

Summit Therapeutics announces $500M common stock offering


Summit Therapeutics files automatic mixed securities shelf

2026-06-09T20:35:40.000Z - 4 weeks ago

Summit Therapeutics files automatic mixed securities shelf


The Era of the One-Size-Fits-All Cancer Drug Is Ending

Jun 6, 2026, 5:30 AM EDT - 4 weeks ago

The Era of the One-Size-Fits-All Cancer Drug Is Ending


Summit Therapeutics Transcript: Status update

Jun 1, 2026, 7:00 AM EDT - 5 weeks ago

Summit Therapeutics Transcript: Status update


Summit Therapeutics Press release: Status update

Jun 1, 2026, 7:00 AM EDT - 5 weeks ago

Summit Therapeutics Press release: Status update


Summit Therapeutics Slides: Status update

Jun 1, 2026, 7:00 AM EDT - 5 weeks ago

Summit Therapeutics Slides: Status update


Summit Therapeutics presents new results from AK112-206 trial

2026-05-31T13:35:51.000Z - 5 weeks ago

Summit Therapeutics presents new results from AK112-206 trial


Summit Therapeutics management to meet with Cantor

2026-05-26T21:01:32.000Z - 6 weeks ago

Summit Therapeutics management to meet with Cantor


Summit Therapeutics Earnings release: Q1 2026

Apr 30, 2026, 4:00 PM EDT - 2 months ago

Summit Therapeutics Earnings release: Q1 2026


Summit Therapeutics Quarterly report: Q1 2026

Apr 30, 2026, 4:00 PM EDT - 2 months ago

Summit Therapeutics Quarterly report: Q1 2026


Summit Therapeutics Proxy statement: Proxy filing

Apr 17, 2026, 8:00 AM EDT - 3 months ago

Summit Therapeutics Proxy statement: Proxy filing


Summit Therapeutics Proxy statement: Proxy filing

Apr 17, 2026, 8:00 AM EDT - 3 months ago

Summit Therapeutics Proxy statement: Proxy filing


Summit Therapeutics Proxy statement: Proxy filing

Apr 6, 2026, 8:00 AM EDT - 3 months ago

Summit Therapeutics Proxy statement: Proxy filing


Summit Therapeutics to Present at Upcoming Investor Conferences

Feb 26, 2026, 6:45 PM EST - 4 months ago

Summit Therapeutics to Present at Upcoming Investor Conferences


Summit Therapeutics Earnings Call Transcript: Q4 2025

Feb 23, 2026, 4:30 PM EST - 4 months ago

Summit Therapeutics Earnings Call Transcript: Q4 2025


Summit Therapeutics Annual report: Q4 2025

Feb 23, 2026, 4:30 PM EST - 4 months ago

Summit Therapeutics Annual report: Q4 2025


Summit Therapeutics Earnings release: Q4 2025

Feb 23, 2026, 4:30 PM EST - 4 months ago

Summit Therapeutics Earnings release: Q4 2025


Summit Therapeutics Slides: Q4 2025

Feb 23, 2026, 4:30 PM EST - 4 months ago

Summit Therapeutics Slides: Q4 2025


Summit Therapeutics Raises $500 Million in Private Placement

Oct 22, 2025, 8:00 AM EDT - 9 months ago

Summit Therapeutics Raises $500 Million in Private Placement


Summit Therapeutics Earnings Call Transcript: Q3 2025

Oct 20, 2025, 8:00 AM EDT - 9 months ago

Summit Therapeutics Earnings Call Transcript: Q3 2025


Summit Therapeutics Earnings release: Q3 2025

Oct 20, 2025, 8:00 AM EDT - 9 months ago

Summit Therapeutics Earnings release: Q3 2025


Summit Therapeutics Quarterly report: Q3 2025

Oct 20, 2025, 8:00 AM EDT - 9 months ago

Summit Therapeutics Quarterly report: Q3 2025


Summit Therapeutics Slides: Q3 2025

Oct 20, 2025, 8:00 AM EDT - 9 months ago

Summit Therapeutics Slides: Q3 2025


Summit Therapeutics Inc. Investigated by the Portnoy Law Firm

Sep 16, 2025, 4:31 PM EDT - 10 months ago

Summit Therapeutics Inc. Investigated by the Portnoy Law Firm


Summit Therapeutics Transcript: Study Update

Sep 8, 2025, 8:00 AM EDT - 10 months ago

Summit Therapeutics Transcript: Study Update


Summit Therapeutics Press release: Study Update

Sep 8, 2025, 8:00 AM EDT - 10 months ago

Summit Therapeutics Press release: Study Update


Summit Therapeutics Slides: Study Update

Sep 8, 2025, 8:00 AM EDT - 10 months ago

Summit Therapeutics Slides: Study Update


Summit Therapeutics Earnings release: Q2 2025

Aug 11, 2025, 7:00 AM EDT - 11 months ago

Summit Therapeutics Earnings release: Q2 2025


Summit Therapeutics Quarterly report: Q2 2025

Aug 11, 2025, 7:00 AM EDT - 11 months ago

Summit Therapeutics Quarterly report: Q2 2025


Is SMMT Stock A Buy After Its Recent Plunge?

Jun 2, 2025, 9:10 AM EDT - 1 year ago

Is SMMT Stock A Buy After Its Recent Plunge?


Final Trade: NVS, XLU and SMMT

May 1, 2025, 6:20 PM EDT - 1 year ago

Final Trade: NVS, XLU and SMMT

NVS XLU


Summit Therapeutics Earnings Call Transcript: Q1 2025

May 1, 2025, 4:30 PM EDT - 1 year ago

Summit Therapeutics Earnings Call Transcript: Q1 2025


Summit Therapeutics Quarterly report: Q1 2025

May 1, 2025, 4:30 PM EDT - 1 year ago

Summit Therapeutics Quarterly report: Q1 2025


Summit Therapeutics Earnings release: Q1 2025

May 1, 2025, 4:30 PM EDT - 1 year ago

Summit Therapeutics Earnings release: Q1 2025


Summit Therapeutics Slides: Q1 2025

May 1, 2025, 4:30 PM EDT - 1 year ago

Summit Therapeutics Slides: Q1 2025


Summit Therapeutics Proxy statement: Proxy Filing

Apr 29, 2025, 8:00 AM EDT - 1 year ago

Summit Therapeutics Proxy statement: Proxy Filing


Dragonland
Dragonland Jul. 10 at 4:05 PM
$SMMT Holding up well considering rest of biotech is a deep red bloodbath today. When they take a sector down, they really don't spare anyone.
0 · Reply
Stbruce1978
Stbruce1978 Jul. 10 at 3:48 PM
$SMMT Very unscientific data point – from Aug 2025 thru May 2026, 100% of my $SMMT allocation was on the fully paid lending list (meaning the shares were actively short by someone else). Starting in June that number dropped to 18% of my allocation. Short interest is drying up – still elevated but not the extremes we saw prior. That’s a positive from a sentiment standpoint. It also means people who are excited for a short squeeze, should probably temper their expectations on that occurring.
1 · Reply
TruthBroker2
TruthBroker2 Jul. 9 at 6:26 PM
$SMMT Fridays Payday.
0 · Reply
SmokeWagon
SmokeWagon Jul. 9 at 3:59 PM
$SMMT !!!
0 · Reply
Megabyte48
Megabyte48 Jul. 9 at 10:40 AM
$SMMT Get over that 16$ today
0 · Reply
TruthBroker2
TruthBroker2 Jul. 8 at 11:20 PM
0 · Reply
HP18
HP18 Jul. 8 at 6:32 PM
$SLS Cleared all my positions in $CAPR and $SMMT to purchase more $SLS shares as can't miss this cheap buying opportunity. Still time to get back in $CAPR before the fda outcome deadline in August.
3 · Reply
SmokeWagon
SmokeWagon Jul. 8 at 2:34 PM
$SMMT !!!
0 · Reply
BapoRothstein
BapoRothstein Jul. 8 at 1:52 AM
$SMMT Chilling with Big Rob at Bob’s Big Boy. We’re waiting on Dr. Clow to meet us. After she gets here we’re going to eat salads with delicious blue cheese dressing and laugh, country club style, at all smelly poor people doubters. And then we’re riding together to massive gains on this excellent stock. Don’t hate me, bro. I don’t make the rules.
0 · Reply
Merlintrader
Merlintrader Jul. 7 at 9:12 PM
$SMMT Summit Therapeutics (Nasdaq: $SMMT): Ivonescimab, PD-1/VEGF Bispecifics and the High-Stakes Oncology Platform Bet https://www.merlintrader.com/summit-therapeutics-stock-hub/
0 · Reply
DarkMatter1
DarkMatter1 Jul. 7 at 4:56 PM
$SMMT woot woot we are up .01 while all other holdings are bleeding out
0 · Reply
TruthBroker2
TruthBroker2 Jul. 7 at 3:06 PM
$SMMT $PLSE Time to go up
0 · Reply
OdaMoney
OdaMoney Jul. 7 at 1:46 PM
$SMMT hope yall caught that fakeout
0 · Reply
SmokeWagon
SmokeWagon Jul. 7 at 11:20 AM
$SMMT !!!
0 · Reply
Megabyte48
Megabyte48 Jul. 7 at 7:30 AM
$SMMT
0 · Reply
OdaMoney
OdaMoney Jul. 7 at 2:24 AM
0 · Reply
OdaMoney
OdaMoney Jul. 7 at 2:24 AM
$SMMT calling 17$ in the next 4 days
0 · Reply
Abundance11
Abundance11 Jul. 6 at 8:01 PM
$SMMT Could honestly squeeze hard.. borrow rates are cheap but if this hits 17+ theres not many shares available out there , this could explode. Duggan Hates shorts!
1 · Reply
TruthBroker2
TruthBroker2 Jul. 6 at 6:10 PM
0 · Reply
Dcvfin
Dcvfin Jul. 6 at 5:30 PM
$SMMT looking pretty good lately
1 · Reply
SmokeWagon
SmokeWagon Jul. 6 at 5:21 PM
$SMMT !!!
0 · Reply
SmartFlowTrading
SmartFlowTrading Jul. 6 at 1:02 PM
$SMMT - Bullish Options Positioning Ahead of Clinical and Regulatory Catalysts Timing is a v important component of the investment case. Summit’s next major clinical catalyst is expected in the second half of 2026, when final progression-free-survival data from the squamous cohort of HARMONi-3 are anticipated. This will be followed by the FDA’s November 14, 2026 PDUFA date for ivonescimab in previously treated EGFR-mutant NSCLC. The final progression-free-survival analysis for the non-squamous HARMONi-3 cohort is expected in the first half of 2027. We have also observed constructive bullish options positioning in SMMT ahead of this catalyst window. While options activity should not be interpreted as predictive of clinical or regulatory outcomes, the positioning is consistent with growing investor attention around the potential for meaningful value inflection through late 2026 and into 2027.
0 · Reply